Xeris Pharmaceuticals | XERS - Interest Expense On Debt


Xeris Pharmaceuticals reported $7.27M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Celltrion KRW 19B 1.96B Jun/2025
Cspc Pharmaceutical CNY 10.19M 4.73M Sep/2025
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Divis Laboratories Ltd INR 30M 20M Jun/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Kangmei Pharma CNY 1.82M 150K Sep/2025
Knight Therapeutics CAD 2.37M 6K Sep/2025
Laboratorios Farma EUR 699K 666.2K Jun/2025
Medical Developments International AUD 18K 3K Jun/2025
Neuren Pharmaceuticals AUD 0 0 Jun/2024
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pharma Mar EUR 117K 1.24M Sep/2025
Qiagen NV USD 8.22M 615K Sep/2025
Sartorius EUR 49.5M 8.1M Sep/2025
Sino Biopharmaceutical CNY 76.87M 114.23M Jun/2024
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Tilray USD 6.7M 2.73M Jun/2025
Zz Pientze Pharmaceu CNY 46.05M 36.5M Jun/2025